MA-PTC
8.5.2019 20:47:12 CEST | Business Wire | Press release
PTC (NASDAQ: PTC) today announced the release of its 2019 “State of Industrial Innovation” report series. The series provides an ongoing review and analysis of the industrial augmented reality (AR) and industrial internet of things (IIoT) markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005784/en/
Among the findings included in the latest “State of Industrial Augmented Reality ” report: AR adoption has become focused on delivering enhanced methods of instruction, guidance, and training for front-line workers, enabling the workforce optimization necessary to address the growing skilled labor shortage the industrial sector faces. According to the “State of the Industrial Internet of Things ” report: IIoT is poised to have a breakout year in 2019 as companies seek to improve operational effectiveness, reduce costs, and decrease risk inherent in the modern competitive landscape. Both reports explore the breadth of the increasingly multifaceted opportunities presented by these markets.
“Organizations in industrial settings realize the urgency in improving productivity and streamlining operations to remain competitive and relevant,” said Jim Heppelmann, president and CEO, PTC. “The insights offered in these reports validate that the adoption of industrial AR and IIoT is an important step toward achieving these goals.”
Highlights from the Report Findings:
The State of Industrial Augmented Reality
- Industrial enterprises are the highest adopters of augmented reality, comprising nearly 60% of the survey responses, with efforts focused on improving worker performance and solving the skilled labor shortage faced by companies worldwide.
- 55% of use cases aimed at improving worker productivity focus on delivering instructions and guidance primarily within manufacturing, service, and training environments.
- Successful pilots are being moved to production within 12 months at a 20% higher rate, year-over-year, allowing early-movers to capitalize on the competitive advantage.
The State of the Industrial Internet of Things
- IoT is becoming commonplace in heavy-industrial environments, with applications expanding across discrete manufacturing in industrial factories representing over 70% of the survey responses.
- Comprehensive, pre-built IIoT solutions are driving more established use cases, such as operational intelligence (31% of total use cases), as well as emerging use cases, such as predictive maintenance (12%) across manufacturing, operations, and service functions.
- Data processing at the device or “edge-layer” (present in 68% of use cases) is a critical capability for solution providers and there are increasing requirements for the same capabilities at the IoT Gateway (37%) and Cloud (34%) layers.
- Industrial enterprises facing global pressures are seeing the need to quickly deploy IIoT to improve operational effectiveness. 89% of respondents to the 2018 IIoT survey are planning to move to production in the next year, up 6% from 2017.
Leveraging PTC’s 30+ years of technology experience and incorporating data from a cross-section of over 30,000 PTC global customers and 1,000 PTC technology and service partners, PTC’s “State of Industrial Innovation” report series provides a comprehensive view of actionable insights and trends across the industrial ecosystem. To learn more about how industrial AR and IIoT can improve workforce optimization and operational effectiveness, download the “State of Industrial Augmented Reality ” and the “State of the Industrial Internet of Things ” 2019 reports.
Additional Resources
- Blog: State of Industrial Augmented Reality 2019 Report Highlights Use Cases in Industrial Enterprises
- Blog: State of Industrial Internet of Things 2019 Report Identifies Key Use Cases Driving Operational Effectiveness
- Harvard Business Review: “Why Every Organization Needs an AR Strategy ,” authored by PTC CEO Jim Heppelmann and Harvard Professor Michael Porter
About PTC (NASDAQ: PTC)
PTC unleashes industrial innovation
with award-winning, market-proven solutions that enable companies to
differentiate their products and services, improve operational
excellence, and increase workforce productivity. With PTC, and its
partner ecosystem, manufacturers can capitalize on the promise of
today’s new technology to drive digital transformation.
PTC, the State of Industrial Innovation series, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005784/en/
Contact:
PTC Corporate Communications Jack McAvoy jmcavoy@ptc.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom